Stockscreener 앱 받기
63.27
0.60%
-0.38
시간 외 거래:
63.75
0.48
+0.76%
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 - GlobeNewswire Inc.
What Has Caused Halozyme Therapeutics (HALO) Shares to Fall 13.1% Following Its Most Recent Earnings Report? - Bitget
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report? - Yahoo Finance Singapore
Halozyme Therapeutics : ESG Key Data & Metrics (rev11 Halozyme ESG Key Data 2026 ISS Corporate comments Mar2026 version 1 for publication) - marketscreener.com
Halozyme (HALO) loses 9% on weak earnings - MSN
Halozyme declines after Q4 bottom line miss, reiterates 2026 guidance - MSN
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference - Yahoo Finance
Alliancebernstein Reduces Stake in Halozyme Therapeutics - National Today
Alliancebernstein L.P. Trims Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story? - simplywall.st
Growth Value: Is Halozyme Therapeutics Inc forming a bullish divergenceWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Brevan Howard Sells Stake in Halozyme Therapeutics - National Today
Brevan Howard Capital Management LP Sells 96,806 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Aquatic Capital Management Buys Stake in Halozyme Therapeutics - National Today
Aquatic Capital Management LLC Acquires Shares of 89,651 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme appoints David Ramsay as interim CFO - MSN
Halozyme Therapeutics, Inc. $HALO Shares Bought by ArrowMark Colorado Holdings LLC - MarketBeat
Halozyme names David Ramsay as interim CFO - Investing.com Nigeria
Halozyme Therapeutics (HALO) Valuation Check After Recent Share Price Pullback - Sahm
Is Halozyme Therapeutics (HALO) Pricing Look Interesting After Recent Share Price Volatility - simplywall.st
Halozyme Therapeutics Receives 'Hold' Rating from Analysts - National Today
2Xideas AG Trims Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness - Yahoo Finance
Kennedy Capital Management LLC Reduces Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme names David Ramsay as interim CFO By Investing.com - Investing.com India
Halozyme Taps David Ramsay as Interim Chief Financial Officer - Contract Pharma
Is Halozyme Therapeutics a Better Buy Than United Therapeutics? - Trefis
Halozyme Names David Ramsay Interim Chief Financial Officer - TipRanks
Halozyme Therapeutics, Inc. Appoints David Ramsay as Interim Chief Financial Officer, Effective March 23, 2026 - marketscreener.com
Halozyme (HALO) Appoints David Ramsay as Interim CFO - GuruFocus
Halozyme (HALO) Appoints Interim CFO Amid Search for Permanent E - GuruFocus
David Ramsay returns as interim CFO at Halozyme (HALO) - Stock Titan
Halozyme Appoints David Ramsay as Interim Chief Financial Officer - marketscreener.com
Capital Fund Management Boosts Stake in Halozyme Therapeutics - National Today
Capital Fund Management S.A. Has $15.60 Million Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme Therapeutics (HALO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations By Investing.com - Investing.com Nigeria
Halozyme at Citizens Life Sciences: Strategic Growth and Innovations - Investing.com
Insider Selling: Cortney Caudill Unloads $1.96M Of Halozyme Therapeutics Stock - Benzinga
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Halozyme Therapeutics COO Sells $599,000 in Shares - National Today
Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 20,000 Shares of Stock - MarketBeat
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery By Investing.com - Investing.com Canada
Halozyme Therapeutics COO Cortney Caudill Sells Shares - TradingView
Halozyme at Leerink Conference: Strategic Advances in Drug Delivery - Investing.com
Halozyme (HALO) COO exercises 21,546 options and sells 28,857 shares - Stock Titan
HALO (NASDAQ: HALO) insider sale notice — 20,000 shares on 03/09/2026 - Stock Titan
Rule 144 sale notice: HALO (NASDAQ: HALO) 20,000 shares via option exercise - Stock Titan
Neo Ivy Capital Management Reduces Stake in Halozyme Therapeutics - National Today
Neo Ivy Capital Management Cuts Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
DLD Asset Management LP Has $2.20 Billion Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Victory Capital Management Trims Halozyme Therapeutics Stake - National Today
Victory Capital Management Inc. Sells 46,430 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report? - MSN
Halozyme To Report Third Quarter 2023 Financial and Operating Re - GuruFocus
Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment - marketscreener.com
1.20%
0.06%
자본화:
|
볼륨(24시간):